litronesib

an Eg5 inhibitor

Also Known As:

(-)-N-(4-(2,2-dimethyl-propionyl)-5-((2-ethylamino-ethanesulfonylamino)-methyl)-5- phenyl-4,5-dihydro-(1,3,4)thiadiazol-2-yl)-2,2-dimethyl-propionamide; (R)-N-(4-(2,2-dimethyl-propionyl)-5-((2-ethylamino-ethanesulfonylamino)-methyl)-5- phenyl-4,5-dihydro-(1,3,4)thiadiazol-2-yl)-2,2-dimethyl-propionamide; KF 89617; KF-89617; KF89617; LY2523355; N-(4-(2,2-dimethyl-propionyl)-5-((2-ethylamino-ethanesulfonylamino)-methyl)-5- phenyl-4,5-dihydro-(1,3,4)thiadiazol-2-yl)-2,2-dimethyl-propionamide

Networked: 4 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Westin, Eric H: 2 articles (02/2017 - 11/2015)
2.	Akinaga, Shiro: 2 articles (11/2015 - 07/2014)
3.	Carradori, Simone: 1 article (08/2018)
4.	Chandrasekaran, Balakumar: 1 article (08/2018)
5.	Cirilli, Roberto: 1 article (08/2018)
6.	Guglielmi, Paolo: 1 article (08/2018)
7.	Karpoormath, Rajshekhar: 1 article (08/2018)
8.	Kozielski, Frank: 1 article (08/2018)
9.	Talapatra, Sandeep K: 1 article (08/2018)
10.	Tham, Chuin Lean: 1 article (08/2018)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2015 - "In vivo efficacy of LY2523355 is highly dose/schedule-dependent, achieving complete remission in a number of xenograft tumor models, including patient-derived xenograft (PDX) tumor models. " 02/01/2017 - "Dose-dependent increases in litronesib plasma exposure were observed, with minor intra- and inter-cycle accumulation, along with exposure-dependent increases in pHH3 expression in tumor and skin biopsies. " 11/01/2015 - "LY2523355 arrests cancer cells at mitosis and causes rapid cell death that requires sustained spindle-assembly checkpoint (SAC) activation with a required threshold concentration. " 11/01/2015 - "A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models." 07/01/2014 - "The recommended dose of LY2523355 with therapeutic G-CSF use for further studies was determined to be 5 mg/m²/day in Japanese patients with advanced solid tumors."
2.	Multiple Myeloma 08/05/2018 - "An inhibitor named K858 has in vivo activity in various mouse xenografts whereas the clinical candidates (S)-ARRY-520 and (R)-Litronesib have entered clinical trials with the former one in phase III clinical trials either alone or in combination with a proteasome inhibitor against relapsed/refractory multiple myeloma. "
3.	Mucositis 02/01/2017 - "Prophylactic pegfilgrastim reduced neutropenia frequency and severity, allowing administration of higher litronesib doses, but increases in the incidences of mucositis and stomatitis were observed. "
4.	Stomatitis 02/01/2017 - "Prophylactic pegfilgrastim reduced neutropenia frequency and severity, allowing administration of higher litronesib doses, but increases in the incidences of mucositis and stomatitis were observed. "
5.	Neutropenia 02/01/2017 - "Prophylactic pegfilgrastim reduced neutropenia frequency and severity, allowing administration of higher litronesib doses, but increases in the incidences of mucositis and stomatitis were observed. "

Related Drugs and Biologics

1.	litronesib
2.	Proteasome Inhibitors
3.	Granulocyte Colony-Stimulating Factor (G-CSF)
4.	Biomarkers (Surrogate Marker)
5.	pegfilgrastim (Neulasta)